Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

NCT02594384 is registered in ClinicalTrials.gov with OrphAI Therapeutics as lead sponsor.

NCT NCT02594384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02594384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Lead sponsor
OrphAI Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2015
Completion date
March 30, 2023
Enrollment
62 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, non-hodgkin; leukemia, chronic lymphocytic